Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

T. Macarulla, A. Cervantes, J. Tabernero, S. Roselló, E. Van Cutsem, S. Tejpar, H. Prenen, E. Martinelli, T. Troiani, B. Laffranchi, V. Jego, O. Von Richter, F. Ciardiello

Research output: Contribution to journalArticleResearchpeer-review

27 Citations (Scopus)

Abstract

© 2015 Cancer Research UK. All rights reserved. Background: The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib. Methods: Patients with KRAS mutant mCRC were treated in the second-line setting with FOLFIRI (5-fluorouracil/folinic acid/irinotecan) plus pimasertib. The primary objective of the safety run-in phase was to determine the maximum-tolerated dose (MTD) and the recommended phase II dose of pimasertib combined with FOLFIRI. Results: Sixteen patients were enrolled in the trial. Ten and six patients were treated daily with 45 and 60 mg of pimasertib plus FOLFIRI, respectively. The MTD was considered to be 45 mg per day. The most common treatment-emergent adverse events were diarrhoea, nausea, vomiting, asthenia and skin/rash event. Of the 15 patients in the efficacy analysis group, two patients had partial response, nine patients had stable disease, three patients had progressive disease as their best overall response and one patient could not be evaluated. Conclusions: Dose escalation of pimasertib in combination with FOLFIRI was limited by toxicity. At the MTD of 45 mg per day, pimasertib was adequately tolerated in patients with mCRC and no unexpected or new safety signals or concerns were identified.
Original languageEnglish
Pages (from-to)1874-1881
JournalBritish Journal of Cancer
Volume112
Issue number12
DOIs
Publication statusPublished - 1 Jan 2015

Keywords

  • FOLFIRI
  • KRAS-mutated metastatic colorectal cancer
  • MEK inhibitor
  • combination therapy second-line treatment
  • pimasertib

Fingerprint

Dive into the research topics of 'Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this